Cargando…
Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial
PURPOSE: In this placebo-controlled trial, we aimed to evaluate the clinical results of using PDE-5 inhibitor, tadalafil 5 mg OD, for management of CP/CPPS. PATIENTS AND METHODS: 140 patients ≤ 45 years old with moderate/severe CP/CPPS associated with ED (IIEF-5 < 22) were randomly divided and re...
Autores principales: | Tawfik, Ahmed M., Radwan, Mohammed H., Abdulmonem, Mohammed, Abo-Elenen, Mohammed, Elgamal, Samir A., Aboufarha, Mohammed O. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512753/ https://www.ncbi.nlm.nih.gov/pubmed/35802142 http://dx.doi.org/10.1007/s00345-022-04074-4 |
Ejemplares similares
-
Correction to: Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial
por: Tawfik, Ahmed M., et al.
Publicado: (2022) -
Once-daily 5 mg tadalafil oral treatment for patients with chronic prostatitis/chronic pelvic pain syndrome
por: Benelli, Andrea, et al.
Publicado: (2018) -
Protective effect of tadalafil on the functional and structural changes of the rat ventral prostate caused by chronic pelvic ischemia
por: Zarifpour, Mona, et al.
Publicado: (2015) -
Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
por: Pattanaik, Smita, et al.
Publicado: (2019) -
Erratum: Efficacy of tamsulosin and tadalafil in relieving benign prostatic hyperplasia related symptoms: A randomized double blind placebo controlled cross-over study
Publicado: (2019)